| II-33 Marcus Baaz Evaluation and Optimization of Model-based Translations in Oncology - From Xenografts to RECIST |
| II-35 Elisa Borella PKPD modelling of MEN1611 anti-tumor effect in xenograft models to predict efficacy threshold concentrations in HER2-positive advanced or metastatic breast cancer patient population |
| II-36 Aurore CARROT Population K-PD modelling of PSA kinetics in patients with recurrent prostate cancer. |
| II-37 Marc Cerou A model-based approach to evaluate the effect of isatuximab in combination with pomalidomide and dexamethasone using multiple composite endpoints: Application to the ICARIA study in relapsed/refractory multiple myeloma |
| II-38 Pascal Chanu A disease model for Multiple Myeloma developed using Real World Data |
| II-39 Jonathan Chauvin A library of tumor growth and tumor growth inhibition models for the MonolixSuite |
| II-40 Wendy Chu Elucidating the effect of platelet binding on vincristine distribution by a physiologically based pharmacokinetic (PBPK) approach |
| II-41 David Damoiseaux Predictiveness of the human CYP3A4 transgenic mouse model (Cyp3aXAV) for human drug exposure assessed using a population pharmacokinetic approach |
| II-42 Nikki de Rouw Costs of pemetrexed-associated neutropenia and the budget impact of pemetrexed dose individualization |
| II-43 Fernandez Teruel Carlos Population Pharmacokinetics of Capivasertib, a Potent Selective AKT Inhibitor, in Patients with Solid Tumours |
| II-44 David Hodson Non linear mixed effects modelling of tumour interactions with the adaptive immune response during Radiotherapy in combination with anti-PDL1 or Olaparib. |
| II-45 Eman Ibrahim Pharmacokinetic-pharmacodynamic (PK-PD) modeling of leukocyte dynamics and lymph node size in chronic lymphocytic leukaemia patients treated with ibrutinib |
| II-46 Itziar Irurzun Arana Ceralasertib-induced haematological toxicity modelling to support monotherapy Recommended Phase 2 Dose determination |
| II-47 Martin Johnson Long short-term memory recurrent neural networks to predict longitudinal changes in tumour size |
| II-48 Yoshimasa Kobayashi Pharmacometric analysis to justify a higher recommended dose for trastuzumab deruxtecan in the treatment of subjects with metastatic gastric cancer versus breast cancer |
| II-49 Naoki Kotani A model based approach to infer overall survival (OS) in hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (HR+/HER2- mBC) |
| II-50 Nataliya Kudryashova The Markov chain survival modeling platform for cancer burden assessment |
| II-51 Rachael Lawson Development of a time dependent clearance model for busulfan in paediatric patients to investigate dosing adjustment scenarios |
| II-52 Xia Li Population-based Target-Mediated Drug Disposition (TMDD) Pharmacokinetics Model of Daratumumab in Patients With Multiple Myeloma Following Intravenously Daratumumab Monotherapy |
| II-53 Sarah Lobet Target-mediated pharmacokinetics of cetuximab: target occupancy influences progression-free survival |
| II-54 Paolo Magni Reduced food-intake and sarcopenia in animal models of cancer anorexia-cachexia syndrome: a Dynamic Energy Budget (DEB)-based modeling approach |
| II-55 Luca Marzano Role of tree-based machine learning algorithms in prognostic pattern detection: an Extensive-Disease Small Cell Lung Cancer (ED-SCLC) study |
| II-56 Zinnia Parra-Guillen Mechanistic modeling of a novel oncolytic virus, V937, to describe viral kinetic and dynamic processes following intratumoral and intravenous administration |
| II-57 Clémence Pouzin Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate. |
| II-58 Alicja Puszkiel Optimisation of the dose and schedule of everolimus and sorafenib combination therapy in patients with solid tumors using a PKPD/time-to-event model |
| II-59 Thomas RODIER Population Pharmacokinetic-Pharmacogenetic Analysis of Osimertinib in patients with Non-Small Cell Lung Cancer |
| II-60 Aymara Sancho Semi-mechanistic model for the antitumor response of a combination cocktail of immune-modulators in non-inflamed (cold tumors) |
| II-61 Eduard Schmulenson Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP) |
| II-62 Gianluca Selvaggio Computational analysis of cytokine release following bispecific T-cell engager therapy |
| II-63 Hinke Siebinga A Population Pharmacokinetic Model to Assess Variability in Pharmacokinetics of 177Lu-PSMA-617 in Low Volume Metastatic Prostate Cancer Patients |
| II-64 Alexandra Smirnova Dose dependence of safety of PD-1 and CTLA-4 checkpoint inhibitors: Comparison of normal-normal and binomial-normal hierarchical models for rare events in a Bayesian meta-analysis framework |
| II-65 Alina Volkova The multivariate baseline and longitudinal biomarker analysis for the survival prediction in NSCLC by means of joint modeling |
| II-66 Xuyang SONG Population Pharmacokinetics Modeling of Monalizumab in Cancer Patients with Longitudinal Patient/Disease Characteristics |
| II-67 Maximilian Strobl Adaptive therapy: Leveraging eco-evolutionary principles to improve resistance management in oncology |
| II-68 Elena Tosca A tumor-in-host Dynamic Energy Budget (DEB)-based paradigm for preclinical to clinical translation: predictions of tumor-in-host growth dynamics |
| II-69 Armando Tratenšek Target-mediated drug disposition model of rituximab in patients with diffuse large B-cell lymphoma |
| II-70 Van Thuy Truong A comparison of ordinary differential equation and agent-based approaches to PKPD modelling in oncology |
| II-72 Maarten Van Eijk Pharmacokinetic and pharmacodynamic modelling of different oral paclitaxel formulations co-administered with ritonavir. |
| II-73 Elena Vasileva Pharmacokinetic, receptor occupancy and pharmacodynamic (PK/RO/PD) modeling of ALX148, a CD47 blocker |
